Screener
Enliven Therapeutics ELVN Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation | 14 | 74 |
| Stock-based compensation | 7,397 | 6,799 |
| Noncash lease expense | 93 | 85 |
| Amortization of premiums and discounts on marketable securities, net | 266 | (45) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and long-term assets | 1,647 | (152) |
| Operating lease liabilities | (97) | (69) |
| Accounts payable | (519) | 220 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Enliven Therapeutics (ELVN) reported accretion (amortization) of discounts and premiums, investments of -$266K in Q1 2026.
- How has Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 691.1% year-over-year, from $45K to -$266K.
- What is the long-term trend for Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2024), Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 39.9% compound annual growth rate (CAGR), from -$155K to -$424K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the non-cash adjustment to the carrying value of investment securities held by the company. It accounts for the amortization of premiums or the accretion of discounts over the life of the investment, impacting the reported operating cash flow without affecting cash balances.
Ask your AI about Enliven Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude